---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-047073"
form_type: "8-K"
ticker: "APLS"
cik: "0001492422"
company_name: "Apellis Pharmaceuticals, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:34:19.174383+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Apellis FY2023 revenue $396.6M, SYFOVRE drives 160k+ doses; net loss $528.6M

## Summary
- Full year 2023 total revenue $396.6M (vs $75.4M in 2022); SYFOVRE $275.2M, EMPAVELI $91.0M.
- SYFOVRE: over 160,000 commercial and sample doses distributed in 2023; Q4 net revenue $114.3M.
- Net loss $528.6M for 2023 (vs $652.2M in 2022); cash $351.2M as of Dec 31, 2023.
- Entered agreements to unwind ~80% of capped calls on convertible notes due 2026; expects ~$100M proceeds.
- G&A expenses rose to $500.8M in 2023 (vs $277.2M in 2022) on SYFOVRE commercial launch costs.

## SEC filing metadata
- accession: 0001193125-24-047073
- form_type: 8-K
- ticker: APLS
- cik: 0001492422
- company_name: Apellis Pharmaceuticals, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/d796432d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-047073
- JSON: https://secwatch.observer/filing/0001193125-24-047073.json
- Plain text: https://secwatch.observer/filing/0001193125-24-047073.txt

## Key facts
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: revenue $396.6 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: $396.6 million
  - Result: reported results
  source text: For the full year 2023, total revenue was $396.6 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm
- Earnings Releases
  Apellis Pharmaceuticals, Inc. reported the fourth quarter ended December 31, 2023 results: revenue $146.4 million.
  - Period: the fourth quarter ended December 31, 2023
  - Revenue: $146.4 million
  - Result: reported results
  source text: Total revenue was $146.4 million for the fourth quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1492422/000119312524047073/0001193125-24-047073-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.